Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

Algosun Global

Equity Capital Markets

<p>A clinical-stage biotech company Kronos Bio, founded by partners and executives from Two River Group, priced its IPO of ~13.1 million shares at price of $19 a share or IPO valuation of ~$1.2B at above the price range. We estimate net proceeds from the offering to reach ~$231 million. Lead underwriters are Goldman Sachs, Jefferies, Cowen and Piper Sandler.</p><p>Kronos Bio was backed by investment and venture capital firms Omega Funds, Vida Ventures, Perceptive Advisors, GV (formerly Google Ventures), Polaris Partners, Invus and established global asset managers Fidelity Investments, T. Rowe Price and Blackrock. According to Crunchbase, Kronos Bio raised ~$278M from sales of preferred stock and convertible debt.</p>

A clinical-stage biotech company Kronos Bio, founded by partners and executives from Two River Group, priced its IPO of ~13.1 million shares at price of $19 a share or IPO valuation of ~$1.2B at above the price range. We estimate net proceeds from the offering to reach ~$231 million. Lead underwriters are Goldman Sachs, Jefferies, Cowen and Piper Sandler.Kronos Bio was backed by investment and venture capital firms Omega Funds, Vida Ventures, Perceptive Advisors, GV (formerly Google Ventures), Polaris Partners, Invus and established global asset managers Fidelity Investments, T. Rowe Price and Blackrock. According to Crunchbase, Kronos Bio raised ~$278M from sales of preferred stock and convertible debt.

Kronos Bio IPO. Gilead’s SYK Inhibitor Portfolio Will Boost The Pipeline

United States

Kronos Bio, Inc. operates as a biotechnology company. The Company discovers and develops therapies that modulate historically recalcitrant cancer targets. Kronos Bio serves customers in worldwide.

Kronos Bio (KRON US)

Kronos Bio IPO. Gilead’s SYK Inhibitor Portfolio Will Boost The Pipeline

A clinical-stage biotech company Kronos Bio, founded by partners and executives from Two River Group, priced its IPO of ~13.1 million shares at...

Andrei Zakharov